Xenetic Biosciences (formally Lipoxen) is a leading biopharmaceutical company operating from the UK that develops high-value, differentiated pharmaceutical products in the fields of protein drugs, vaccines and anti-cancer drugs.
The company has developed a range of proprietary patented technologies that are being used to create a new generation of drug and vaccine products with improved performance. Xenetic Biosciences 's technologies include: PolyXen® - Protein drug delivery, ImuXen® - DNA, protein and polysaccharide vaccines and VesicALL® - Anti-cancer drugs using liposomal entrapment.
Xenetic Biosciences suspends open offer part of fundraising
1st Feb 2012, 11:05 am by Andre Lamberti
Biopharmaceutical firm () has decided not to pursue an open offer fundraising at this time.
The offer was first proposed to coincide with the acquisition of German firm SymbioTec, which was first agreed in August last year. That deal took longer to close than initially expected.
Xenetic now believes it is in the company's best interests to drop the open offer at this time.
The Symbio completion proved to be a protracted process, it said. And in the months leading up to the completion, market uncertainties saw its share price fall to an eventual low of 6.5 pence on November 22.
“Against this background, and in spite of the completion (on January 16), the 9 pence share price at close of business on January 31 2012 remains below the open offer price of 11 pence per share.
"The directors have therefore determined that in these circumstances it is not in the best interests of the company to implement the open offer at this time,” the group said.
Xenetic bought SymbioTec with the help of Russian firm Synbio, which invested £12.2 million through the purchase of 110.8 million shares at a price of 11 pence each.
The proposed open-offer was intended to offer existing shareholders the opportunity to also invest on the same terms.
No investment advice
The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
